Overdose with a mometasone furoate inhaler may occur with chronic overuseFDA LabelF4292. Symptoms of chronic overuse may present as hypercorticism and adrenal suppression, and patients may not require any more treatment than monitoringFDA LabelF4292.
In animal studies of pregnancy, some fetal toxic effects were seen at or above the maximum recommended human dose, though rodents are more sensitive to these effects than humansFDA LabelF4292,F4295. The benefits and risks of use should be considered in pregnant patientsF4292,F4295
It is unknown if mometasone furoate is excreted in breast milk but other corticosteroids are and therefore caution should be exercised when administering to nursing mothersFDA LabelF4292,F4295.
Safety and effectiveness in pediatric populations has been established through clinical trials, though there may be a reduction in expected growth of about 1cm per year depending on the dose and duration of treatmentFDA Label. Pediatric patients should be titrated to the lowest effective dose for mometasone furoate inhalersFDA Label.
A trial of geriatric patients showed no difference in safety or efficacy compared to younger patients, however patients of an even greater age may still be more sensitive to mometasone furoateFDA LabelF4292,F4295.
The use of a mometasone furoate inhaler in moderate or severe hepatic impairment rarely leads to detectable plasma concentrations though caution may be prudent with increasing degrees of severityFDA LabelF4292.
The effects of mometasone furoate in renal impairment, and across gender and race have not been studiedFDA LabelF4292.
Mometasone furoate is a corticosteroid drug that can be used for the treatment of asthma, rhinitis, and certain skin conditionsFDA LabelF4292,F4295. It has a glucocorticoid receptor binding affinity 22 times stronger than dexamethasone and higher than many other corticosteroids as wellA176906. Mometasone furoate is formulated as a dry powder inhaler, nasal spray, and ointment for its different indicationsFDA LabelF4292,F4295.
Fitur visualisasi ini dikembangkan menggunakan pendekatan Graph Theory untuk memetakan hubungan polifarmasi dan molekuler. Entitas (Obat, Target, Gen) direpresentasikan sebagai Simpul (Nodes), sedangkan hubungan biologisnya sebagai Sisi (Edges).
drugbank-id dan name pada skema XML DrugBank.targets/target yang memuat polipeptida sasaran.gene-name dan varian snp-effects.Tata letak grafik menggunakan algoritma Force-Directed Graph (Barnes-Hut). Model fisika ini menerapkan gaya tolak-menolak antar simpul (Gravitasi: -3000) agar tidak tumpang tindih, serta gaya pegas (Spring: 0.04) pada garis penghubung untuk fleksibilitas interaksi.
| Denosumab | The risk or severity of adverse effects can be increased when Denosumab is combined with Mometasone furoate. |
| Peginterferon alfa-2a | The risk or severity of adverse effects can be increased when Peginterferon alfa-2a is combined with Mometasone furoate. |
| Interferon alfa-n1 | The risk or severity of adverse effects can be increased when Interferon alfa-n1 is combined with Mometasone furoate. |
| Interferon alfa-n3 | The risk or severity of adverse effects can be increased when Interferon alfa-n3 is combined with Mometasone furoate. |
| Peginterferon alfa-2b | The risk or severity of adverse effects can be increased when Peginterferon alfa-2b is combined with Mometasone furoate. |
| Interferon gamma-1b | The risk or severity of adverse effects can be increased when Interferon gamma-1b is combined with Mometasone furoate. |
| Interferon alfa-2a | The risk or severity of adverse effects can be increased when Interferon alfa-2a is combined with Mometasone furoate. |
| Gemtuzumab ozogamicin | The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Mometasone furoate. |
| Pegaspargase | The serum concentration of Mometasone furoate can be increased when it is combined with Pegaspargase. |
| Interferon beta-1b | The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Mometasone furoate. |
| Interferon alfacon-1 | The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Mometasone furoate. |
| Rituximab | The risk or severity of adverse effects can be increased when Rituximab is combined with Mometasone furoate. |
| Basiliximab | The risk or severity of adverse effects can be increased when Basiliximab is combined with Mometasone furoate. |
| Muromonab | The risk or severity of adverse effects can be increased when Muromonab is combined with Mometasone furoate. |
| Ibritumomab tiuxetan | The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Mometasone furoate. |
| Tositumomab | The risk or severity of adverse effects can be increased when Tositumomab is combined with Mometasone furoate. |
| Alemtuzumab | The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Mometasone furoate. |
| Alefacept | The risk or severity of adverse effects can be increased when Alefacept is combined with Mometasone furoate. |
| Efalizumab | The risk or severity of adverse effects can be increased when Efalizumab is combined with Mometasone furoate. |
| Antithymocyte immunoglobulin (rabbit) | The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Mometasone furoate. |
| Interferon alfa-2b | The risk or severity of adverse effects can be increased when Interferon alfa-2b is combined with Mometasone furoate. |
| Daclizumab | The risk or severity of adverse effects can be increased when Daclizumab is combined with Mometasone furoate. |
| Phenylalanine | The risk or severity of adverse effects can be increased when Phenylalanine is combined with Mometasone furoate. |
| Cladribine | Mometasone furoate may increase the immunosuppressive activities of Cladribine. |
| Carmustine | The risk or severity of adverse effects can be increased when Carmustine is combined with Mometasone furoate. |
| Amsacrine | The risk or severity of adverse effects can be increased when Amsacrine is combined with Mometasone furoate. |
| Bleomycin | The risk or severity of adverse effects can be increased when Bleomycin is combined with Mometasone furoate. |
| Chlorambucil | The risk or severity of adverse effects can be increased when Chlorambucil is combined with Mometasone furoate. |
| Raltitrexed | The risk or severity of adverse effects can be increased when Raltitrexed is combined with Mometasone furoate. |
| Mitomycin | The risk or severity of adverse effects can be increased when Mitomycin is combined with Mometasone furoate. |
| Bexarotene | The risk or severity of adverse effects can be increased when Bexarotene is combined with Mometasone furoate. |
| Floxuridine | The risk or severity of adverse effects can be increased when Floxuridine is combined with Mometasone furoate. |
| Tioguanine | The risk or severity of adverse effects can be increased when Tioguanine is combined with Mometasone furoate. |
| Dexrazoxane | The risk or severity of adverse effects can be increased when Dexrazoxane is combined with Mometasone furoate. |
| Streptozocin | The risk or severity of adverse effects can be increased when Streptozocin is combined with Mometasone furoate. |
| Trifluridine | The risk or severity of adverse effects can be increased when Trifluridine is combined with Mometasone furoate. |
| Gemcitabine | The risk or severity of adverse effects can be increased when Gemcitabine is combined with Mometasone furoate. |
| Epirubicin | The risk or severity of adverse effects can be increased when Epirubicin is combined with Mometasone furoate. |
| Chloramphenicol | The risk or severity of adverse effects can be increased when Chloramphenicol is combined with Mometasone furoate. |
| Lenalidomide | The risk or severity of adverse effects can be increased when Lenalidomide is combined with Mometasone furoate. |
| Altretamine | The risk or severity of adverse effects can be increased when Altretamine is combined with Mometasone furoate. |
| Zidovudine | The risk or severity of adverse effects can be increased when Zidovudine is combined with Mometasone furoate. |
| Oxaliplatin | The risk or severity of adverse effects can be increased when Oxaliplatin is combined with Mometasone furoate. |
| Propylthiouracil | The risk or severity of adverse effects can be increased when Propylthiouracil is combined with Mometasone furoate. |
| Pentostatin | The risk or severity of adverse effects can be increased when Pentostatin is combined with Mometasone furoate. |
| Linezolid | The risk or severity of adverse effects can be increased when Linezolid is combined with Mometasone furoate. |
| Clofarabine | The risk or severity of adverse effects can be increased when Clofarabine is combined with Mometasone furoate. |
| Pemetrexed | The risk or severity of adverse effects can be increased when Pemetrexed is combined with Mometasone furoate. |
| Mycophenolate mofetil | The risk or severity of adverse effects can be increased when Mycophenolate mofetil is combined with Mometasone furoate. |
| Tretinoin | The metabolism of Tretinoin can be increased when combined with Mometasone furoate. |
| Dacarbazine | The risk or severity of adverse effects can be increased when Dacarbazine is combined with Mometasone furoate. |
| Temozolomide | The risk or severity of adverse effects can be increased when Temozolomide is combined with Mometasone furoate. |
| Penicillamine | The risk or severity of adverse effects can be increased when Penicillamine is combined with Mometasone furoate. |
| Azacitidine | The risk or severity of adverse effects can be increased when Azacitidine is combined with Mometasone furoate. |
| Carboplatin | The risk or severity of adverse effects can be increased when Carboplatin is combined with Mometasone furoate. |
| Dactinomycin | The risk or severity of adverse effects can be increased when Dactinomycin is combined with Mometasone furoate. |
| Azathioprine | The risk or severity of adverse effects can be increased when Azathioprine is combined with Mometasone furoate. |
| Hydroxyurea | The risk or severity of adverse effects can be increased when Hydroxyurea is combined with Mometasone furoate. |
| Mycophenolic acid | The risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Mometasone furoate. |
| Topotecan | The risk or severity of adverse effects can be increased when Topotecan is combined with Mometasone furoate. |
| Mercaptopurine | The risk or severity of adverse effects can be increased when Mercaptopurine is combined with Mometasone furoate. |
| Thalidomide | The risk or severity of adverse effects can be increased when Thalidomide is combined with Mometasone furoate. |
| Melphalan | The risk or severity of adverse effects can be increased when Melphalan is combined with Mometasone furoate. |
| Fludarabine | The risk or severity of adverse effects can be increased when Fludarabine is combined with Mometasone furoate. |
| Flucytosine | The risk or severity of adverse effects can be increased when Flucytosine is combined with Mometasone furoate. |
| Capecitabine | The risk or severity of adverse effects can be increased when Capecitabine is combined with Mometasone furoate. |
| Procarbazine | The risk or severity of adverse effects can be increased when Procarbazine is combined with Mometasone furoate. |
| Arsenic trioxide | The risk or severity of adverse effects can be increased when Arsenic trioxide is combined with Mometasone furoate. |
| Idarubicin | The risk or severity of adverse effects can be increased when Idarubicin is combined with Mometasone furoate. |
| Estramustine | The risk or severity of adverse effects can be increased when Estramustine is combined with Mometasone furoate. |
| Mitoxantrone | The risk or severity of adverse effects can be increased when Mitoxantrone is combined with Mometasone furoate. |
| Lomustine | The risk or severity of adverse effects can be increased when Lomustine is combined with Mometasone furoate. |
| Eculizumab | The risk or severity of adverse effects can be increased when Eculizumab is combined with Mometasone furoate. |
| Decitabine | The risk or severity of adverse effects can be increased when Decitabine is combined with Mometasone furoate. |
| Nelarabine | The risk or severity of adverse effects can be increased when Nelarabine is combined with Mometasone furoate. |
| Stepronin | The risk or severity of adverse effects can be increased when Stepronin is combined with Mometasone furoate. |
| Hydroxychloroquine | The risk or severity of adverse effects can be increased when Hydroxychloroquine is combined with Mometasone furoate. |
| Castanospermine | The risk or severity of adverse effects can be increased when Castanospermine is combined with Mometasone furoate. |
| Vorinostat | The risk or severity of adverse effects can be increased when Vorinostat is combined with Mometasone furoate. |
| 2-Methoxyethanol | The risk or severity of adverse effects can be increased when 2-Methoxyethanol is combined with Mometasone furoate. |
| Brequinar | The risk or severity of adverse effects can be increased when Brequinar is combined with Mometasone furoate. |
| Pirfenidone | The risk or severity of adverse effects can be increased when Pirfenidone is combined with Mometasone furoate. |
| Interferon alfa | The risk or severity of adverse effects can be increased when Interferon alfa is combined with Mometasone furoate. |
| Glatiramer | The risk or severity of adverse effects can be increased when Glatiramer is combined with Mometasone furoate. |
| Briakinumab | The risk or severity of adverse effects can be increased when Briakinumab is combined with Mometasone furoate. |
| Human interferon omega-1 | The risk or severity of adverse effects can be increased when Human interferon omega-1 is combined with Mometasone furoate. |
| Mepolizumab | The risk or severity of adverse effects can be increased when Mepolizumab is combined with Mometasone furoate. |
| Abetimus | The risk or severity of adverse effects can be increased when Abetimus is combined with Mometasone furoate. |
| Belatacept | The risk or severity of adverse effects can be increased when Belatacept is combined with Mometasone furoate. |
| Bendamustine | The risk or severity of adverse effects can be increased when Bendamustine is combined with Mometasone furoate. |
| Pralatrexate | The risk or severity of adverse effects can be increased when Pralatrexate is combined with Mometasone furoate. |
| Wortmannin | The risk or severity of adverse effects can be increased when Wortmannin is combined with Mometasone furoate. |
| Eribulin | The risk or severity of adverse effects can be increased when Eribulin is combined with Mometasone furoate. |
| Belimumab | The risk or severity of adverse effects can be increased when Belimumab is combined with Mometasone furoate. |
| Teriflunomide | The risk or severity of adverse effects can be increased when Teriflunomide is combined with Mometasone furoate. |
| Carfilzomib | The risk or severity of adverse effects can be increased when Carfilzomib is combined with Mometasone furoate. |
| Dimethyl fumarate | The risk or severity of adverse effects can be increased when Dimethyl fumarate is combined with Mometasone furoate. |
| Obinutuzumab | The risk or severity of adverse effects can be increased when Obinutuzumab is combined with Mometasone furoate. |
| Vedolizumab | The risk or severity of adverse effects can be increased when Vedolizumab is combined with Mometasone furoate. |
| Blinatumomab | The risk or severity of adverse effects can be increased when Blinatumomab is combined with Mometasone furoate. |